allogeneic stem cell transplantation
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical procedure
|
| gptkbp:alternativeTo |
autologous stem cell transplantation
|
| gptkbp:canBe |
adults
children elderly patients |
| gptkbp:canBeComplicatedBy |
gptkb:chronic_graft-versus-host_disease
relapse secondary malignancies |
| gptkbp:canBeCurativeFor |
gptkb:acute_myeloid_leukemia
gptkb:anemia aplastic anemia leukemia sickle cell disease immunodeficiency myelodysplastic syndromes |
| gptkbp:canBePrecededBy |
radiation therapy
chemotherapy |
| gptkbp:cause |
gptkb:graft-versus-host_disease
mixed chimerism immune reconstitution full donor chimerism graft-versus-leukemia effect |
| gptkbp:donorType |
cord blood donor
haploidentical donor related donor unrelated donor |
| gptkbp:firstPerformed |
1957
|
| gptkbp:followedBy |
immunosuppressive therapy
engraftment monitoring |
| https://www.w3.org/2000/01/rdf-schema#label |
allogeneic stem cell transplantation
|
| gptkbp:inventedBy |
gptkb:E._Donnall_Thomas
|
| gptkbp:NobelPrizeYear |
Nobel Prize in Physiology or Medicine 1990
|
| gptkbp:requires |
supportive care
immunosuppression HLA matching pre-transplant evaluation long-term follow-up conditioning regimen |
| gptkbp:riskFactor |
gptkb:graft-versus-host_disease
infection graft failure organ toxicity |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:source |
bone marrow
umbilical cord blood peripheral blood stem cells |
| gptkbp:usedFor |
treatment of hematologic malignancies
treatment of bone marrow failure syndromes treatment of genetic disorders |
| gptkbp:usesDonorCells |
yes
|
| gptkbp:bfsParent |
gptkb:aggressive_systemic_mastocytosis
gptkb:CMML gptkb:Primary_Myelofibrosis gptkb:acute_graft-versus-host_disease |
| gptkbp:bfsLayer |
7
|